ВОЗМОЖНОСТИ КОМПЬЮТЕРНОЙ ТОМОГРАФИИ В ДИАГНОСТИКЕ МНОЖЕСТВЕННОЙ МИЕЛОМЫ
Аннотация
Введение. Множественная миелома (МнМ) – парапротеинемический гемобластоз, характеризующийся деструктивным поражением скелета, развитием почечной недостаточности, анемии, гиперкальциемии. Цель. Изучение возможностей компьютерной томографии в выявлении МнМ. Материал и методы. Проанализированы русскоязычные и англоязычные источники. Представлены клинические случаи, демонстрирующие возможности компьютерной томографии в диагностике МнМ. Результаты. Представленный обзор раскрывает вопросы этиологии, клиники и диагностики МнМ. Продемонстрированы характерные признаки МнМ не только в костях скелета, а также во внутренних органах. Выводы. Множественную миелому нужно рассматривать как заболевание, затрагивающее множество органов и систем организма. Компьютерная томография – ведущий метод диагностики литических поражении костей при МнМ.
Литература
Rejnberg SA. Mielomnaja bolezn. In: Rejnberg SA. Rentgenodiagnostika zabolevanij kostej i sustavov. Vol. II. Moskva: Medicina; 1964. p. 444-461. (Russian).
Kravchenko DV, Hoduleva SA, Novik DK. Mnozhestvennaja mieloma. Gomel: Respublikanskij nauchno prakticheskij centr radiacionnoj mediciny i jekologii cheloveka; 2016. p. 5-8. (Russian).
Uss AL. Terapija recidivirujushhej i rezistentnoj formy mnozhestvennoj mielomy i Respublike Belarus [Therapy of relapsed and refractory multiple myeloma form in Belarus]. Voennaja medicina [Military medicine]. 2015;(4):83-87. (Russian).
Vojcehovskij VV, Landyshev JuS, Grigorenko AA, Celujko SS, Goborov ND. Mnozhestvennaja mieloma. Sovremennye principy diagnostiki i lechenija. Blagoveshhensk; 2012. p. 14-18. (Russian).
International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749-57. https://doi.org/10.1046/j.1365-2141.2003.04355.x.
Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23(1):3-9. https://doi.org/10.1038/leu.2008.291.
Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36(3):842-54. https://doi.org/10.1002/1097-0142(197509)36:3(842::aid-cncr2820360303)3.0.co;2-u.
Davies FE, Wu P, Jenner M, Srikanth M, Saso R, Morgan GJ. The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone. Haematologica. 2007;92(8):1149-50. https://doi.org/10.3324/haematol.11228.
Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348(26):2609-17. https://doi.org/10.1056/NEJMoa030288.
Zappasodi P, Dore R, Castagnola C, Astori C, Varettoni M, Mangiacavalli S, Lazzarino M, Corso A. Rapid response to high-dose steroids of severe bortezomib-related pulmonary complication in multiple myeloma. J Clin Oncol. 2007;25(22):3380-1. https://doi.org/10.1200/JCO.2006.10.0164.
Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi NC, Treon SP, Anderson KC. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002;99(12):4525-30. https://doi.org/10.1182/blood.v99.12.4525.
Breitkreutz I, Raab MS, Vallet S, Hideshima T, Raje N, Mitsiades C, Chauhan D, Okawa Y, Munshi NC, Richardson PG, Anderson KC. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia. 2008;22(10):1925-32. https://doi.org/10.1038/leu.2008.174.
Hussain S, Browne R, Chen J, Parekh S. Lenalidomideinduced severe hepatotoxicity. Blood. 2007;110(10):3814. https://doi.org/10.1182/blood-2007-06-097758.
Moreau P, San Miguel J, Ludwig H, Schouten H, Mohty M, Dimopoulos M, Dreyling M; ESMO Guidelines Working Group. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):133-7. https://doi.org/10.1093/annonc/mdt297.
Schuster SR, Rajkumar SV, Dispenzieri A, Morice W, Aspitia AM, Ansell S, Kyle R, Mikhael J. IgM multiple myeloma: disease definition, prognosis, and differentiation from Waldenstrom’s macroglobulinemia. Am J Hematol. 2010;85(11):853-5. https://doi.org/10.1002/ajh.21845.
Davies FE, Wu P, Jenner M, Srikanth M, Saso R, Morgan GJ. The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone. Haematologica. 2007;92(8):1149-50. https://doi.org/10.3324/haematol.11228.
Moulopoulos LA, Granfield CA, Dimopoulos MA, Kim EE, Alexanian R, Libshitz HI. Extraosseous multiple myeloma: imaging features. Am J Roentgenol. 1993;161(5):1083-7. https://doi.org/10.2214/ajr.161.5.8273615.
Agarwal A, Chirindel A, Shah BA, Subramaniam RM. Evolving role of FDG PET/CT in multiple myeloma imaging and management. Am J Roentgenol. 2013;200(4):884-90. https://doi.org/10.2214/AJR.12.9653.
Baur-Melnyk A, Buhmann S, Becker C, Schoenberg SO, Lang N, Bartl R, Reiser MF. Whole-body MRI versus whole-body MDCT for staging of multiple myeloma. Am J Roentgenol. 2008;190(4):1097-104. https://doi.org/10.2214/AJR.07.2635.
Baur-Melnyk A, Buhmann S, Dürr HR, Reiser M. Role of MRI for the diagnosis and prognosis of multiple myeloma. Eur J Radiol. 2005;55(1):56-63. https://doi.org/10.1016/j.ejrad.2005.01.017.
Dutoit JC, Verstraete KL. MRI in multiple myeloma: a pictorial review of diagnostic and post-treatment findings. Insights Imaging. 2016;7(4):553-69. https://doi.org/10.1007/s13244-016-0492-7.
